You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A monoclonal antibody treatment from Eli Lilly may slow the progression of Alzheimer's disease, the New York Times reports.
Both of the RT-PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in a variety of swab samples and other specimens.
The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.
Two experimental drugs were unable to slow or prevent Alzheimer's disease among people at high genetic risk, the Associated Press reports.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
Screening of disease-linked cell types might bolster drug discovery efforts in schizophrenia, according to a proof-of-concept study.
The funding is being provided by Genome Canada, as well as various Canadian provinces, businesses, and research institutes.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.